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The paper by Dal Negro et al. [1] raises a number of
interesting issues. Patients with severe chronic obstruct-
ive pulmonary disease (COPD) were ranked according to
hemoglobin in a program of monitored long term domi-
ciliary oxygen therapy (LTOT). Good therapeutic com-
pliance (mean 17 hours/24 hour day) using liquid
oxygen at a flow rate of 2.3 L per minute, presumably
through nasal cannulae, was achieved. This is remark-
able: few schemes achieve such good adherence. Patients
were mostly male, ex-smokers of mean age 71.4 years, of
average body weight with few markedly over- or
underweight.
Blood hemoglobin ranged from moderately anaemic
levels to frankly polycythemic. Anemic patients tended
to be under weight raising the issues, as the authors dis-
cuss, of the consequences of systemic inflammatory dis-
ease, in some cases of advanced emphysematous COPD.
The most interesting finding in this small study was
the striking improvement not only in PaO2 but in
PaCO2 with a trend to continuing benefit throughout
the period. Similarly, hemoglobin crept in from the ex-
treme limits to a normal middle range. Whilst it would
not be surprising for polycythemia to redress, the idea
that systemic inflammation might be reversible, indi-
cated by a rising hemoglobin in response to LTOT in
advanced COPD with emphysema, is notable.
It is approaching 40 years since the original domicil-
iary oxygen therapy trials [2,3] were conducted in the
UK and USA. It is worth comparing the type of patients
enrolled in those trials with those treated today. In the
UK, the mean age of the patients was in the early 50’s
compared with over 70 years today. They suffered
advanced COPD, were generally overweight, very edema-
tous, polycythemic with hypoxemia and hypercapnia, the
latter often severe. Hypercapnia limited the application
of supplementary oxygen by its increase under oxygen
administration. There was an increase in survival in the
oxygen treated group through relief of extreme hypox-
emia with no evidence to suggest attenuation or
improvement of progressive COPD. The net result was
an extension of life for two to three years.
Since then, the natural history of COPD has changed.
The time course of the pathological features has
extended. Whilst death from COPD remains a major
health issue, it is now a disorder predominantly of the
over-70 years of age. Respiratory failure develops some
20–30 years later than it used to.
Is it the same disease? There is now less extreme
hypercapnia [4], obesity, edema, polycythemia but more
underweight, extreme dyspnea, anemia and systemic
markers of inflammation. It is still considered an inevit-
ably progressive disorder for which current therapies
provide amelioration rather than reversal of the destruc-
tive processes.
This paper raises the question as to whether there is a
therapeutic window during the now prolonged natural
history to end-stage disease and death when therapeutic
interventions such as well controlled LTOT might fur-
ther attenuate outcome. This study is too small to reply
to this question, but provides a challenge to the authors
to engage in a much bigger, probably multi-center,
study.
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